The common inflammatory etiology of depression and cognitive impairment: a therapeutic target

Journal of Neuroinflammation

David S Ditor¹  David J Allison¹ 

[1] Department of Kinesiology, Faculty of Applied Health Science, Brock University, 500 Glenridge Ave, St. Catharines L2S 3A1, ON, Canada

关键词: Exercise;    Cognitive impairment;    Depression;    Chronic Inflammation;    Kynurenine pathway;    Tryptophan 2,3-dioxygenase;    Indoleamine 2,3-dioxygenase;   

Others  :  1150922
DOI  :  10.1186/s12974-014-0151-1

 received in 2014-07-02, accepted in 2014-08-13,  发布年份 2014

【 摘 要 】

Chronic inflammation has been shown to contribute to the development of a wide variety of disorders by means of a number of proposed mechanisms. Depression and cognitive impairment are two such disorders which may share a closely linked inflammatory etiology. The ability of inflammatory mediators to alter the activity of enzymes, from key metabolic pathways, may help explain the connection between these disorders. The chronic up-regulation of the kynurenine pathway results in an imbalance in critical neuroactive compounds involving the reduction of tryptophan and elevation of tryptophan metabolites. Such imbalances have established implications in both depression and cognitive impairment. This may implicate the immune system as a potential therapeutic target in the treatment of these disorders. The most common treatment modalities currently utilized, involve drug interventions which act on downstream targets. Such treatments help to reestablish protein balances, but fail to treat the inflammatory basis of the disorder. The use of anti-inflammatory interventions, such as regular exercise, may therefore, contribute to the effectiveness of current drug interventions in the treatment of both depression and cognitive impairment.

【 授权许可】

   
2014 Allison and Ditor; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Felger JC, Lotrich FE: Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
• [2]Schiepers OJG, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
• [3]McAfoose J, Baune BT: Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009, 33:355-366.
• [4]Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol 2011, 29:415-445.
• [5]Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
• [6]Festa A, D¿Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
• [7]Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M: Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002, 45:151.
• [8]Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890.
• [9]Maier SF, Goeler LE, Fleshner M, Watkins LR: The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci 1998, 840:289-300.
• [10]Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci 1995, 57:1011-1026.
• [11]Banks WA, Ortiz L, Plotkin SR, Kastin AJ: Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 1991, 259:988-996.
• [12]Chesnokova V, Melmed S, Angeles CL, Angeles L: Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling. Molecules 2014, 143:1571-1574.
• [13]Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J: Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992, 22:45-53.
• [14]Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25-46.
• [15]Sluzewska A: Indicators of immune activation in depressed patients. Adv Exp Med Biol 1999, 461:59-73.
• [16]Tobinick E: Tumour necrosis factor modulation for treatment of Alzheimer¿s disease rationale and current evidence. CNS Drugs 2009, 23:713-725.
• [17]Oxenkrug GF: Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci 2007, 1122:35-49.
• [18]Gál EM, Sherman AD: L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 1980, 5:223-239.
• [19]Oxenkrug GF: Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci 2010, 47:56-63.
• [20]Kanai M, Nakamura T, Funakoshi H: Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res 2009, 64:111-117.
• [21]Dang Y, Dale WE, Brown OR: Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med 2000, 28:615-624.
• [22]Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR: Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991, 56:2007-2017.
• [23]Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ: Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001, 78:842-853.
• [24]Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000, 164:3596-3599.
• [25]Shirey KA, Jung J-Y, Maeder GS, Carlin DJM: Upregulation of IFN-? receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. J Interf Cytokine Res 2006, 26:53-62.
• [26]Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310:850-855.
• [27]Fallarino F, Grohmann U, Vacca C, Bianchi R: T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002, 9:1069-1077.
• [28]Owe-Young R, Webster NL, Mukhtar M, Pomerantz RJ, Smythe G, Walker D, Armati PJ, Crowe SM, Brew BJ: Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem 2008, 105:1346-1357.
• [29]Zhu C-B, Blakely RD, Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
• [30]Morikawa O, Sakai N, Obara H, Saito N: Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998, 349:317-324.
• [31]Delgado P: Serotonin function and the mechanism of antidepressant action by. Arch Gen Psychiatry 1990, 47:411-418.
• [32]Culley WJ, Saunders RN, Mertz ET, Jolly DH: Effect of a tryptophan deficient diet on brain serotonin and plasma tryptophan level. Proc Soc Exp Biol Med 1963, 113:645-648.
• [33]Gal EM, Drewes PA: Studies on the metabolism of 5-hydroxytryptamine (serotonin). II. Effect of tryptophan deficiency in rats. Proc Soc Exp Biol Med 1962, 110:368-371.
• [34]Carpenter LL, Anderson GM, Pelton GH, Gudin JA, Kirwin PD, Price LH, Heninger GR, McDougle CJ: Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1998, 19:26-35.
• [35]Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, Blier P, Diksic M: Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci 1997, 94:5308-5313.
• [36]Okuda S, Nishiyama N, Saito H, Katsuki H: 3-hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 2002, 70:299-307.
• [37]Braidy N, Grant R, Adams S, Guillemin GJ: Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 2010, 277:368-382.
• [38]Stokes PE: The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur Neuropsychopharmacol 1995, 5:77-82.
• [39]Pariante CM: Depression, stress and the adrenal axis. J Neuroendocrinol 2003, 15:811-812.
• [40]Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS: Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115-118.
• [41]Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004, 161:1957-1966.
• [42]Sheline YI: Untreated depression and Hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
• [43]Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM: Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011, 8:94. BioMed Central Full Text
• [44]Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA: Urinary free cortisol excretion in depression. Psychol Med 1976, 6:43-50.
• [45]Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7:468-473.
• [46]Lotrich FE: Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009, 11:417-425.
• [47]Kessing LV: Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998, 28:1027-1038.
• [48]Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM: Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998, 172:527-532.
• [49]Bender DA, McCreanor GM: Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 1985, 13:441-443.
• [50]Alkondon M, Pereira EFR, Yu P, Arruda EZ, Almeida LEF, Guidetti P, Fawcett WP, Sapko MT, Randall WR, Schwarcz R, Tagle DA, Albuquerque EX: Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J Neurosci 2004, 24:4635-4648.
• [51]Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu H-Q, Schwarcz R: Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010, 35:1734-1742.
• [52]Rassoulpour A, Wu H-Q, Ferre S, Schwarcz R: Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 2005, 93:762-765.
• [53]Zmarowski A, Wu H-Q, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, Bruno JP: Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009, 29:529-538.
• [54]Wu H-Q, Pereira EFR, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R: The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci 2010, 40:204-210.
• [55]Chess AC, Simoni MK, Alling TE, Bucci DJ: Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007, 33:797-804.
• [56]Chess AC, Bucci DJ: Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 2006, 170:326-332.
• [57]Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
• [58]Gulaj E, Pawlak K, Bien B, Pawlak D: Kynurenine and its metabolites in Alzheimer¿s disease patients. Adv Med Sci 2010, 55:204-211.
• [59]Tobinick E, Gross H, Weinberger A, Cohen H: TNF-alpha modulation for treatment of Alzheimer¿s disease: a 6-month pilot study. MedGenMed 2006, 8:25.
• [60]Tobinick EL, Gross H: Rapid cognitive improvement in Alzheimer¿s disease following perispinal etanercept administration. J Neuroinflammation 2008, 5:2. BioMed Central Full Text
• [61]Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
• [62]Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
• [63]Fitzgerald P, O¿Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006, 36:37-43.
• [64]Nierenberg AA, Alpert JE: Depressive breakthrough. Psychiatr Clin North Am 2000, 23:731-742.
• [65]Coyle JT, Tsai G: The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004, 174:32-38.
• [66]Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR: Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008, 165:1040-1047.
• [67]Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP: Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008, 165:82-89.
• [68]Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT: The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164:1593-1602.
• [69]Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T: Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004, 310:933-942.
• [70]Mathur N, Pedersen BK: Exercise as a Mean to Control Low-Grade Systemic Inflammation. 2008. 2008.
• [71]Petersen AMW, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol 2005, 98:1154-1162.
• [72]Ford ES: Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002, 13:561-568.
• [73]Albert MA, Glynn RJ, Ridker PM: Effect of physical activity on serum C-reactive protein. Am J Cardiol 2004, 93:221-225.
• [74]Abramson JL, Vaccarino V: Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 2002, 162:1286-1292.
• [75]Tomaszewski M, Charchar FJ, Przybycin M, Crawford L, Wallace AM, Gosek K, Lowe GD, Zukowska-Szczechowska E, Grzeszczak W, Sattar N, Dominiczak AF: Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go? Arterioscler Thromb Vasc Biol 2003, 23:1640-1644.
• [76]Fiers W: Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991, 285:199-212.
• [77]Mizuhara H, O¿Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujiwara H: T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994, 179:1529-1537.
• [78]Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK: Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003, 17:884-886.
• [79]Keller C, Keller P, Giralt M, Hidalgo J, Pedersen BK: Exercise normalises overexpression of TNF-alpha in knockout mice. Biochem Biophys Res Commun 2004, 321:179-182.
• [80]Van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996, 97:713-719.
• [81]Kasapis C, Thompson PD: The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005, 45:1563-1569.
• [82]Weight LM, Alexander D, Jacobs P: Strenuous exercise: analogous to the acute-phase response? Clin Sci (Lond) 1991, 81:677-683.
• [83]Fallon KE: The acute phase response and exercise: the ultramarathon as prototype exercise. Clin J Sport Med 2001, 11:38-43.
• [84]Morimoto Y, Zhang Q, Adachi K: Increased blood quinolinic acid after exercise in mice: implications for sensation of fatigue after exercise. J Heal Sci 2011, 57:367-371.
• [85]Ito Y, Saito K, Maruta K, Nakagami Y, Koike T, Oguri Y, Nagamura Y: Kynurenine concentration of serum was increased by exercise. Adv Exp Med Biol 1999, 467:717-722.
• [86]Di Luigi L, Botrè F, Sabatini S, Sansone M, Mazzarino M, Guidetti L, Baldari C, Lenzi A, Caporossi D, Romanelli F, Sgrò P: Acute effects of physical exercise and phosphodiesterase¿s type 5 inhibition on serum 11?-hydroxysteroid dehydrogenases related glucocorticoids metabolites: a pilot study.Endocrine 2014. in press.
• [87]Salter M, Pogson CI: The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J 1985, 229:499-504.
• [88]Da Silva AE, de Aquino LV, Ruiz da Silva F, Lira FS, dos Santos RVT, Rosa JPP, Caperuto E, Tufik S, de Mello MT: Low-grade inflammation and spinal cord injury: exercise as therapy? Mediators Inflamm 2013, 2013:971841.
• [89]Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO: Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005, 28:1-8.
• [90]Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, Herman S, Craighead WE, Brosse AL, Waugh R, Hinderliter A, Sherwood A: Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med ?, 69:587-596.
• [91]Rimer J, Dwan K, Lawlor DA, Greig CA, McMurdo M, Morley W, Mead GE: Exercise for depression. Cochrane database Syst Rev 2012, 7:CD004366.
• [92]Gligoroska JP, Manchevska S: The effect of physical activity on cognition - physiological mechanisms. Mater Sociomed 2012, 24:198-202.